ESC 365 - SGLT2 inhibitors are associated with development of heart failure with improved ejection fraction

ESC Professional Premium Access

SGLT2 inhibitors are associated with development of heart failure with improved ejection fraction

Session: Optimisation of heart failure treatment

Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)

Speaker: Doctor X. Wang (Shanghai, CN)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Xiaoqun Wang

Rui Jin Hospital- Shanghai Jiaotong University School of Medicine, Shanghai (China)

1 follower

8 more presentations in this session

Up-titration of Guideline Directed Medical Therapy (GDMT) and the occurrence of side effects in Heart Failure with reduced Ejection Fraction (HFrEF)

Speaker: Doctor N. Panagiotides (Vienna, AT)

Visit-to-visit changes in heart rate in heart failure: a pooled participant-level analysis of the PARADIGM-HF and PARAGON-HF trials

Speaker: Doctor H. Lu (Boston, US)

Use and associations with mortality/morbidity of guideline-directed medical therapy use in heart failure with improved ejection fraction: a PS-matched analysis from the swedish heart failure registry

Speaker: Doctor C. Basile (Naples, IT)

Survival benefit of guideline-directed medical therapy in elderly patients with heart failure with reduced ejection fraction: a systematic review and meta-analysis

Speaker: Doctor E. Tan (Singapore, SG)

Differences in the optimization of pharmacological treatment in patients with heart failure and reduced ejection fraction and advanced chronic kidney disease.

Speaker: Doctor A. Recio Mayoral (Seville, ES)

Access the full session

Optimisation of heart failure treatment

Speakers: Doctor X. Wang, Doctor N. Panagiotides, Doctor H. Lu, Doctor C. Basile, Doctor E. Tan...

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources